# ARHGEF33

## Overview
ARHGEF33 is a gene that encodes the protein Rho guanine nucleotide exchange factor 33, which is a member of the guanine nucleotide exchange factors (GEFs) family. This protein plays a pivotal role in the regulation of Rho GTPases, which are essential for various cellular processes, including cell morphology, movement, and cytoskeletal dynamics. By facilitating the exchange of GDP for GTP on Rho proteins, ARHGEF33 activates these GTPases, thereby influencing signaling pathways that control the organization of the actin cytoskeleton. This regulation is crucial for processes such as cell adhesion, motility, and division. The gene's involvement in cellular signaling and structural integrity underscores its importance in tissue development and repair. Additionally, mutations in ARHGEF33 have been implicated in cancer progression, highlighting its clinical significance in oncology (Ishaque2018Whole; Sugiyama2020The).

## Function
ARHGEF33, also known as Rho guanine nucleotide exchange factor 33, plays a crucial role in the regulation of Rho GTPases, which are pivotal for various cellular processes. This protein facilitates the exchange of GDP for GTP on Rho proteins, thereby activating them. Once activated, Rho GTPases transmit signals that significantly influence cell morphology and movement. These processes are essential for maintaining cytoskeletal dynamics, which are critical for cell migration and cell cycle progression. By modulating these activities, ARHGEF33 contributes to the proper functioning of cellular structures and the coordination of cell movement, which are vital for tissue development and repair. The activity of ARHGEF33 is primarily localized within the cell where it interacts with Rho proteins to initiate signaling pathways that control the organization of the actin cytoskeleton. This regulation is fundamental for processes such as cell adhesion, motility, and division, highlighting the importance of ARHGEF33 in maintaining cellular integrity and function.

## Clinical Significance
Mutations and alterations in the ARHGEF33 gene have been implicated in various diseases, particularly in cancer. In colorectal cancer, ARHGEF33 mutations are noted to be mutually exclusive with KRAS mutations, suggesting a similar role in cancer progression. These mutations are associated with worse disease-free survival, indicating their potential impact on patient outcomes and their possible influence on the effectiveness of EGFR-based therapies (Allgayer2020Defining; Ishaque2018Whole). The presence of ARHGEF33 mutations in colorectal cancer is also linked with aneuploidy and TP53 mutations, highlighting its role in tumor progression and metastasis (Ishaque2018Whole).

In gastric signet ring cell carcinoma (SRCC), ARHGEF33 is involved in cell adhesion pathways, which are crucial for tumorigenesis. Mutations in ARHGEF33, along with other regulatory factors of RHOA, suggest its involvement in the development of SRCC, although specific clinical implications remain to be fully elucidated (Shu2018Prognostic; Machlowska2019&lt; State; p&gt).

Overall, the clinical significance of ARHGEF33 mutations lies in their potential to influence cancer progression and treatment outcomes, warranting further investigation into their role in various cancers.

## Interactions
ARHGEF33, also known as Rho guanine nucleotide exchange factor 33, is involved in interactions with the small GTPase RhoA. The protein's guanine nucleotide exchange factor (GEF) activity facilitates the exchange of GDP for GTP on RhoA, thereby activating it. This interaction was demonstrated using a pull-down assay with GST-fused Rhotekin-RBD beads, which specifically bind to active RhoA. The assay showed that the presence of ARHGEF33 significantly increased the amount of active RhoA, indicating a direct interaction between ARHGEF33 and RhoA (Sugiyama2020The).

ARHGEF33's interaction with RhoA is implicated in cellular processes such as cell contraction and neurite outgrowth inhibition. In HEK293 cells, overexpression of ARHGEF33 led to cell contraction, an effect that was reduced by the Rho-associated protein kinase (ROCK) inhibitor Y27632, suggesting that ARHGEF33 activates the RhoA/ROCK signaling pathway. Similarly, in Neuro 2A cells, ARHGEF33 inhibited neurite outgrowth, an effect reversed by the same ROCK inhibitor, further supporting its role in modulating RhoA activity (Sugiyama2020The). These interactions highlight ARHGEF33's role in regulating cellular morphology and signaling pathways through its interaction with RhoA.


## References


[1. (Allgayer2020Defining) Heike Allgayer, Jörg H. Leupold, and Nitin Patil. Defining the “metastasome”: perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences. Seminars in Cancer Biology, 60:1–13, February 2020. URL: http://dx.doi.org/10.1016/j.semcancer.2019.07.018, doi:10.1016/j.semcancer.2019.07.018. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.semcancer.2019.07.018)

[2. (Ishaque2018Whole) Naveed Ishaque, Mohammed L. Abba, Christine Hauser, Nitin Patil, Nagarajan Paramasivam, Daniel Huebschmann, Jörg Hendrik Leupold, Gnana Prakash Balasubramanian, Kortine Kleinheinz, Umut H. Toprak, Barbara Hutter, Axel Benner, Anna Shavinskaya, Chan Zhou, Zuguang Gu, Jules Kerssemakers, Alexander Marx, Marcin Moniuszko, Miroslaw Kozlowski, Joanna Reszec, Jacek Niklinski, Jürgen Eils, Matthias Schlesner, Roland Eils, Benedikt Brors, and Heike Allgayer. Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nature Communications, November 2018. URL: http://dx.doi.org/10.1038/s41467-018-07041-z, doi:10.1038/s41467-018-07041-z. This article has 104 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-018-07041-z)

[3. (Shu2018Prognostic) Yang Shu, Weihan Zhang, Qianqian Hou, Linyong Zhao, Shouyue Zhang, Jiankang Zhou, Xiaohai Song, Yan Zhang, Dan Jiang, Xinzu Chen, Peiqi Wang, Xuyang Xia, Fei Liao, Dandan Yin, Xiaolong Chen, Xueyan Zhou, Duyu Zhang, Senlin Yin, Kun Yang, Jianping Liu, Leilei Fu, Lan Zhang, Yuelan Wang, Junlong Zhang, Yunfei An, Hua Cheng, Bin Zheng, Hongye Sun, Yinglan Zhao, Yongsheng Wang, Dan Xie, Liang Ouyang, Ping Wang, Wei Zhang, Meng Qiu, Xianghui Fu, Lunzhi Dai, Gu He, Hanshuo Yang, Wei Cheng, Li Yang, Bo Liu, Weimin Li, Biao Dong, Zongguang Zhou, Yuquan Wei, Yong Peng, Heng Xu, and Jiankun Hu. Prognostic significance of frequent cldn18-arhgap26/6 fusion in gastric signet-ring cell cancer. Nature Communications, June 2018. URL: http://dx.doi.org/10.1038/s41467-018-04907-0, doi:10.1038/s41467-018-04907-0. This article has 103 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-018-04907-0)

[4. (Sugiyama2020The) Takefumi Sugiyama, Haruka Yamamoto, Tetsuo Kon, Taro Chaya, Yoshihiro Omori, Yutaka Suzuki, Kentaro Abe, Dai Watanabe, and Takahisa Furukawa. The potential role of arhgef33 rhogef in foveal development in the zebra finch retina. Scientific Reports, December 2020. URL: http://dx.doi.org/10.1038/s41598-020-78452-6, doi:10.1038/s41598-020-78452-6. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-020-78452-6)